Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Segments

Common Size IS
Op Efficiency
Credit Analysis

Keros Therapeutics, Inc. (KROS)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-21Dec-31-20Dec-31-19Dec-31-18
   10-K10-K10-KS-1
Total revenues  20.10.010.010.0
            Revenue growth   -100.0%0.0% 
Cost of goods sold  0.00.00.00.0
Gross profit  20.10.010.010.0
            Gross margin  100.0% 100.0%100.0%
Selling, general and administrative   [+]21.312.83.21.6
Research and development  55.133.917.410.1
Other operating expenses   1.52.60.0
EBITDA   [+]-56.0-47.9-12.9-1.6
            EBITDA margin  -278.6% -129.2%-15.8%
Depreciation and amortization  0.40.30.20.2
EBIT   [+]-56.4-48.1-13.1-1.7
            EBIT margin  -280.5% -131.3%-17.3%
Non-recurring items   [+] -1.5-2.60.0
Interest expense, net   [+]0.00.00.00.0
Other income (expense), net  -0.41.1-1.80.6
Pre-tax income  -56.7-45.5-12.3-1.1
Income taxes  2.0-0.20.00.3
            Tax rate   0.4%0.0% 
Net income  -58.7-45.4-14.1-2.3
            Net margin  -292.3% -141.4%-23.5%
   
Basic EPS   [+]($2.52)($2.93)($6.08)($1.08)
Diluted EPS   [+]($2.52)($2.93)($6.08)($1.08)
   
Shares outstanding (basic)   [+]23.315.52.32.2
Shares outstanding (diluted)   [+]23.315.52.32.2
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy